Periodontitis-associated salivary microbiota exacerbates systemic osteoclastogenesis via gut modulation and tryptophan metabolism suppression in ovariectomized miceOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined how salivary microbiota from periodontitis patients affects systemic bone metabolism, using saliva from 17 healthy donors and 21 periodontitis patients, then testing effects in ovariectomized mice.
How was it studied?
Salivary microbiota was gavaged into ovariectomized mice, gut microbiota effects were confirmed via fecal microbiota transplant, cecal metabolomics identified tryptophan pathway changes, and indole-3-lactic acid (ILA) was tested on osteoclast cultures and in vivo.
What did they find?
Periodontitis patients had more diverse salivary microbiota with more pathogenic bacteria, and this microbiota worsened bone loss in mice via gut dysbiosis and suppressed tryptophan metabolism. Its metabolite ILA directly inhibited osteoclast differentiation; ILA supplementation increased bone volume fraction 1.3-fold, trabecular number 1.2-fold, and reduced osteoclast numbers 52% in treated mice.
Why it matters
The findings identify an oral-gut-bone axis linking periodontitis to osteoporosis and suggest ILA supplementation as a potential therapy to counter bone loss from periodontal disease.